<DOC>
	<DOC>NCT00960934</DOC>
	<brief_summary>The purpose of this study was to identify an appropriate dose of MK-5442 that produced an osteoanabolic effect without causing hypercalcemia in postmenopausal women with osteoporosis.</brief_summary>
	<brief_title>A Dose-Ranging Study of MK-5442 in Postmenopausal Women With Osteoporosis (MK-5442-001)</brief_title>
	<detailed_description>Amendment 4 of the protocol changed the duration of the study from 2 years to 6 months.</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<mesh_term>Calcium Carbonate</mesh_term>
	<criteria>Postmenopausal for at least 5 years No history of fragility fracture, unless participant is not willing to take marketed osteoporosis therapy or is not a candidate for marketed osteoporosis therapy Agrees not to use medications for osteoporosis except medications associated with the study Areal bone mineral density (BMD) Tscore &lt;2.5 at one or more of the following 4 BMD sites: total hip, femoral neck, trochanter, or lumbar spine and is ≥ 3.5 at all 4 BMD sites. Participants unwilling to take or ineligible for marketed osteoporosis therapy may have one or more areal BMD Tscores of &lt; 3.5 Unable to undergo dualenergy Xray absorptiometry (DXA) scan due to obesity (ie, weight &gt;250 lbs) Use of oral bisphosphonates in the 6 months prior to study screening, for more than 3 months in the past 2 years, or lifetime use of more than 6 months Use of intravenous bisphosphonates, strontium, or growth hormone at any time Use of phenytoin or heparin within 2 weeks prior to Visit 1; use of raloxifene within 6 months prior to Visit 1 Use of pioglitazone or rosiglitazone at study screening Use of estrogen ± progestin, in any form other than vaginal or topical application, for 6 months prior to Study Visit 1 Prior total thyroidectomy Human immunodeficiency virus (HIV) positive or acquired immune deficiency syndrome (AIDS)related illness History of malignant cancer within 5 years of study screening, except for certain skin or cervical cancers History of Paget's disease and/or kidney stones An active user of any illicit drug History of or active alcohol abuse Participated in an investigational drug study within the past 30 days</criteria>
	<gender>Female</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Osteoporosis</keyword>
	<keyword>Postmenopausal</keyword>
	<keyword>MK-5442</keyword>
</DOC>